Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial.
By G. Salles, J. Seymour, F. Offner, A. López-Guillermo, D. Belada, L. Xerri, P. Feugier, R. Bouabdallah, J. Catalano, P. Brice and 20 more. The Lancet, 2011
1,032 citations recorded by the source corpus.
Subfields: Dermatology, Pathology and Forensic Medicine, Reproductive Medicine
View Paper: https://www.semanticscholar.org/paper/4653079d6f6295f977d9c2c949a30309ee6a8a49
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
- M. Maurer
- John Hainsworth
- Xiaolei Zhou
- C. Flowers
- James R. Cerhan
- A. Zelenetz
- J. Friedberg
- C. Farber
Citations in the corpus
- Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study. (2015, background): “This remains the case despite the benefit of additional rituximab in the form of maintenance, as shown in the PRIMA (Primary Rituximab and Maintenance) study.(12) The remarkably consistent frequency of early relapse across studies is suggestive of a group of patients with different disease JOURNAL O”